Market Currents
Amarin (AMRN -5.9%) took a big hit today after noting in a filing yesterday that it doesn't...
-
Tuesday, September 11, 2012, 6:13 PM ETAmarin (AMRN -5.9%) took a big hit today after noting in a filing yesterday that it doesn't expect a decision from the FDA this month on the exclusivity of its heart pill Vascepa. This marks the second straight month a decision on Vascepa has failed to make the FDA's monthly "Orange Book" update. The ruling is a highly anticipated one that could award the company sole marketing rights to the drug.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 10 comments:
Long Amrn
According to some analysts the stock price could between $18.00 - $22.00 depending on circumstances.
He is truly ridiculous... and his behaviour seems almost intentionally criminal.
Adam's using his free speech... right?
Then I'll use mine: please check the following page for some facts on Adam Feuerstein: http://bit.ly/zcz1QE
Please spread this page as much as you can.
The sooner he is exposed, the sooner we can all invest without a constant fear of a dishonest guy bashing our stocks.
Anyway, with 67% short float... any kind of short covering on SPPI would be epic. They'd probably need over a month to cover all those outstanding shares...